Aurobindo intros generic Gleevec
Imatinib mesylate tablets have a market value of roughly $324 million for the 12 months ended January 2021, according to IQVIA.
Aurobindo is releasing imatinib mesylate tablets, in dosage strengths of 100 mg and 400 mg.
The product is the generic of Novartis’ Gleevec. The medication’s indications include newly diagnosed adult and pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase; as well as patients with Ph+ CML in blast crisis, accelerated phase, or in the chronic phase after failure of interferon-alpha therapy.
Imatinib mesylate tablets have a market value of roughly $324 million for the 12 months ended January 2021, according to IQVIA.